Sarcopenia doubles mortality and amputation risk in diabetic foot patientsMuscle loss increases death and amputation risks for diabetic foot
Frontiers in MedicinePublished August 22, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider sarcopenia as a potential risk marker in diabetic foot, but avoid using it for clinical decisions until confirmed.
This meta-analysis pooled data from 9 studies involving 2,888 adults aged 18 years or older with diabetic foot. The analysis compared patients with sarcopenia and muscle attenuation to those without, focusing on mortality, amputation, and ulcer severity. The findings indicate a significant association between sarcopenia and adverse outcomes in this population.
For all-cause mortality, sarcopenia was associated with a hazard ratio of 2.38 (95% CI: 1.63–3.48), indicating a more than doubled risk. Similarly, the odds of amputation were elevated (OR = 2.11, 95% CI: 1.32–3.38). Additionally, patients with sarcopenia had a higher proportion of severe ulcers (Wagner grade 4–5), with a relative risk of 1.69 (95% CI: 1.31–2.17).
The authors note that the evidence is observational and heterogeneous, which limits the certainty of these findings. They emphasize that the results are hypothesis-generating and should not yet be used to support prognostic screening or clinical risk-stratification decisions. The association does not establish causation.
While the data suggest that sarcopenia may be a marker of increased risk in diabetic foot patients, the lack of interventional data and the observational nature of the included studies preclude definitive clinical recommendations. Further research with more rigorous designs is needed to confirm these associations and explore potential interventions.
How this fits prior evidence
This meta-analysis extends prior coverage on diabetic foot risk factors by quantifying the prognostic impact of sarcopenia. It confirms and strengthens earlier observational findings, such as the Tardivo Algorithm study, by showing that sarcopenia is associated with a 2.38-fold higher mortality risk and a 2.11-fold higher amputation odds. It also aligns with the UACR study by highlighting another modifiable risk factor (sarcopenia) that could inform risk stratification, though the authors caution against immediate clinical use due to observational, heterogeneous evidence.
Living with diabetes can take a heavy toll on the body, often leading to complications in the feet. New research highlights a specific risk factor that may make these complications even harder to manage: sarcopenia, which is the loss of muscle mass and strength.
Researchers looked at data from nearly 3,000 people with diabetic foot issues. They found that those with muscle loss were more than twice as likely to face amputation compared to those without it. These patients also showed a higher risk of developing severe ulcers and a significantly higher risk of death overall.
While these findings are important for understanding the risks involved, the evidence comes from observational data, which means we cannot say for certain that muscle loss causes these outcomes. The data was also varied across different studies. Because of this, doctors should not use these results yet to make specific clinical decisions or risk scores for patients.
What this means for you:
Muscle loss in people with diabetic foot is linked to higher rates of severe ulcers, amputation, and death.
Common questions
What are the risks for patients with muscle loss?
People with a diabetic foot who also experience sarcopenia (muscle loss) face significant risks. The data shows they have more than double the risk of amputation and a higher likelihood of developing severe ulcers. Additionally, these individuals showed a much higher risk of death compared to those without muscle loss.
How serious are the ulcers in patients with muscle loss?
Patients with sarcopenia were found to have a higher proportion of severe ulcers (Wagner grade 4 to 5) than those without muscle loss. This suggests that losing muscle mass may be linked to more severe complications for the foot.
Can these results be used to make medical decisions right now?
Not yet. Because the evidence comes from observational data and varied sources, the findings are currently used to generate ideas rather than provide a specific tool for doctors to use in clinical risk-stratification or screening decisions.
BackgroundDiabetic foot (DF) represents a severe and disabling complication of diabetes, closely linked to ulceration, amputation, functional impairment, and an elevated risk of death. Sarcopenia is a syndrome marked by progressive declines in muscle mass and function. Emerging evidence suggests a possible link between DF and sarcopenia. Nonetheless, a systematic evaluation of the influence of sarcopenia on adverse clinical outcomes in individuals with DF remains unavailable. The present investigation aims to systematically assess and quantitatively synthesize the association of sarcopenia and muscle attenuation with clinical outcomes in those with DF.MethodsA systematic search of Embase, Cochrane, PubMed, Web of Science, SinoMed, China National Knowledge Infrastructure, Wanfang, and VIP databases was conducted from their inception through December 2025. Observational studies enrolling DF individuals aged ≥ 18 years and comparing clinical prognoses between those with and without sarcopenia and muscle attenuation were included. The primary outcomes comprised rates of mortality and amputation. Secondary outcomes encompassed ulcer severity. The NHLBI was adopted for risk-of-bias evaluation. Given substantial between-study heterogeneity, a narrative synthesis was prioritized, with meta-analyses implemented for outcomes amenable to quantitative pooling.ResultsEighteen studies (9 cross-sectional, 4 prospective cohort, 4 retrospective cohort, and 1 retrospective case-control studies) comprising 2,888 individuals were included, of which 9 contributed to the meta-analysis. The meta-analysis revealed that, relative to those without sarcopenia and muscle attenuation, DF individuals with comorbid sarcopenia exhibited an elevated risk of all-cause mortality (HR = 2.38, 95% CI: 1.63–3.48), an association with amputation (OR = 2.11, 95% CI: 1.32–3.38), and a higher proportion of severe ulcers (Wagner grade 4–5) (RR = 1.69, 95% CI: 1.31–2.17).ConclusionsImpaired muscle health was associated with a higher risk of all-cause mortality, higher odds of amputation, and a greater prevalence of severe ulcers in patients with DF. Because the available evidence is observational and heterogeneous, these findings should be considered hypothesis-generating and should not yet be used to support prognostic screening or clinical risk-stratification decisions. Future prospective cohort investigations are necessary to further clarify the temporal relationship and underlying mechanisms.Funding and registrationThis study was supported by the Ningxia Natural Science Foundation (Grant Number: 2025AAC030725). This systematic review complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD420251247873).Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420251247873.
